The chronic pain market, valued at $15 billion in 2025, is projected to grow at a compound annual rate of 5% through 2036. This expansion is fueled by an aging global population and rising rates of musculoskeletal conditions, including arthritis and neuropathic pain. As reliance on traditional opioids faces increased scrutiny due to safety concerns, pharmaceutical developers are shifting focus toward targeted, long-acting formulations and gene therapies designed to address specific pain pathways.
Chronic Pain Market Poised for 5% Growth Through 2036
With roughly 115 million diagnosed cases across seven major global markets in 2025, the chronic pain sector is bracing for a decade of transformation. A pipeline of novel non-opioid therapies and interventional treatments is set to redefine care standards as the industry moves beyond traditional pharmacological approaches.
Industry leaders are currently advancing a robust pipeline of candidates, including Saol Therapeutics' SL1002, Novo Nordisk's Zenagamtide, and Vertex Pharmaceuticals' suzetrigine. These emerging drugs aim to provide sustained relief while reducing the frequency of retreatment. According to Sadaf Javed of DelveInsight, the integration of minimally invasive interventional therapies represents a critical evolution, offering patients improved convenience and potentially reducing the burden on healthcare resources. With several Phase III trials nearing completion, the coming years are expected to see a significant diversification of treatment options for patients managing long-term pain conditions.
Comments (0)
No comments yet. Be the first!